Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC versus INDERAL LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC versus INDERAL LA.
BETOPTIC vs INDERAL LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Propranolol is a non-selective beta-adrenergic receptor antagonist that competitively blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure; also inhibits renin release and reduces sympathetic outflow.
Instill 1 drop of 0.5% solution in the affected eye(s) twice daily.
Initial: 80 mg orally once daily; titrate to 120-160 mg once daily; maximum 640 mg/day.
None Documented
None Documented
Terminal elimination half-life: 4–5 hours. With topical ophthalmic administration, systemic absorption is minimal, so half-life refers to IV data.
Terminal elimination half-life is 8-11 hours (range 4-16 hours) after oral administration. The extended-release formulation (INDERAL LA) results in a prolonged half-life of approximately 10 hours, allowing once-daily dosing.
Renal (fecal <5%). 60% as unchanged drug, 40% as inactive metabolites.
Primarily hepatic metabolism with renal elimination of metabolites. Less than 1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 20% of eliminated dose.
Category C
Category C
Beta-Blocker
Beta-Blocker